Predicting Molecular Activity via Functional Pathways

37 concepts29 papers1 proposal

For decades, computer-aided drug discovery has relied on a foundational premise: molecules with similar structures will exhibit similar biological behaviors. This structure-centric paradigm allows researchers to screen billions of candidate molecules by comparing their 2D fingerprints or 3D shapes against known drugs.

However, this assumption frequently fails in practice. In complex biological systems, the relationship between a molecule's physical structure and its ultimate therapeutic effect is often decoupled. This phenomenon—the structural-functional gap—presents a dual challenge: minor chemical modifications can completely invert a drug's function, while entirely different chemical skeletons can trigger identical biological responses.

To overcome these limitations, a growing body of research shifts the focus away from what a molecule looks like and toward how a biological system responds to it. By mapping molecules to a shared space of functional pathways, transcriptomic changes, and phenotypic profiles, researchers can predict molecular activity with far greater fidelity than structural metrics allow.

The Breakdown of Structural Similarity

To understand why traditional metrics fail, we must look at how small chemical changes manifest inside a cell. In a purely structure-based model, molecules are evaluated by their geometry. But biology does not read a molecule's structure as an isolated blueprint; it experiences it as a dynamic set of interactions.

This disconnect manifests in two distinct ways:

  1. Activity Cliffs and Functional Divergence: A tiny structural modification can cause a massive, non-linear shift in biological activity. For example, as Andrea Nuzzo et al. demonstrated in Expanding the drug discovery space with predicted metabolite–target interactions, a natural metabolite might act as a receptor agonist, while its synthetic structural analog acts as an antagonist. Structural similarity metrics view these molecules as nearly identical, completely missing the opposite downstream signaling outcomes they induce.
  2. Scaffold Hopping and Functional Convergence: Conversely, molecules with completely unrelated core frameworks can achieve identical therapeutic effects. As Suleiman A. Khan et al. noted in Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs, traditional structural similarity metrics routinely fail to identify these functionally equivalent compounds because they lack obvious shared motifs. This structural non-uniformity creates severe bottlenecks for generative models; as Seojin Kim et al. explained in Data-Efficient Molecular Generation with Hierarchical Textual Inversion, it is incredibly difficult to capture the essence of a functional class within a single structural representation when the constituent molecules look nothing alike.

Ultimately, analyzing a compound based purely on its molecular scaffold can identify candidates that lack the necessary functional properties or exhibit unforeseen toxicity, a limitation highlighted by Sheng Tian et al. in [Drug-likeness analysis of traditional Chinese medicines:

  1. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines](/work/drug-likeness-analysis-of-traditional-chinese-medicines-2).

Why Functional Convergence Occurs

How can structurally diverse molecules produce identical biological outcomes? The answer lies in the multi-layered architecture of biological systems, which creates functional redundancy at both the molecular and systemic levels.

Interaction Redundancy

At the protein level, different molecular shapes can achieve the same atomic goals. In Fragment libraries designed to be functionally diverse recover protein binding information more efficiently than standard structurally diverse libraries, Anna Carbery et al. discovered that molecules with completely distinct core scaffolds frequently form identical protein-ligand interactions. Traditional chemical library design prioritizes structural diversity as a proxy for functional diversity, assuming different shapes explore different binding mechanisms. However, the authors showed that this approach introduces massive redundancy, repeatedly sampling the same interaction space under different structural guises.

Pathway Convergence

Even when molecules bind to entirely different proteins, they can still converge on the same downstream therapeutic outcome. Cells process signals through interconnected networks rather than isolated linear tracks. As Marc Streit illustrated through the visual analytics framework in ConTour: Data-Driven Exploration of Multi-Relational Datasets for Drug Discovery, compounds with distinct chemical structures often exhibit nearly identical biological effects because they interact with different components of the exact same signaling cascade.

This pathway convergence explains why structural similarity is an unreliable predictor for complex phenomena like drug-drug interactions or drug repurposing. As Lucreția Udrescu et al. argued in Uncovering new drug properties in target-based drug-drug similarity networks, molecular shape does not correlate with how a drug interacts with complex biological systems, meaning hidden therapeutic properties are fundamentally driven by network connectivity rather than structural appearance.

Capturing the Biological Fingerprint

To bypass the limitations of molecular geometry, modern computational models treat the cell as a sensor. Instead of predicting activity from a molecule's static 2D or 3D structure, models use the biological changes induced by the molecule as a dynamic "functional fingerprint."

Traditional Paradigm:
[Chemical Structure] ───(Similarity Metric)───> [Predicted Activity] (Fails at Activity Cliffs/Scaffold Hopping)

Functional Pathway Paradigm:
[Chemical Structure] ───> [Cellular Perturbation] ───> [Pathway Convergence Space] ───> [Accurate Activity Prediction]
                          (Omics / Phenotypes)         (Shared Biological Targets)

Transcriptomics and Multi-Omics

One of the most direct ways to measure a cell's response to a molecule is by tracking gene expression. Bingrui Li et al. demonstrated the power of this approach in A novel drug repurposing approach for non-small cell lung cancer using deep learning, combining transcriptomic fingerprints with chemical structures to successfully identify an antipsychotic drug as a potent treatment for lung cancer.

When single omics layers are insufficient, integrating multiple layers provides a holistic view of a drug's Mode of Action (MoA). Natasha Leanna Patel-Murray et al. developed a multi-omics framework in A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules that uncovers how drugs work by mapping transcriptomics, metabolomics, and proteomics onto physical interaction networks. Their model proved that compounds with completely unrelated structures can converge on identical cellular pathways, such as activating autophagy.

Phenotypic Profiling

Another powerful proxy for function is cellular morphology—the visible, structural changes a cell undergoes when treated with a compound. In Large scale compound selection guided by cell painting reveals activity cliffs and functional relationships, Maxime Sanchez et al. bypassed chemical structures entirely, using deep learning to select compounds based on phenotypic similarity from Cell Painting images. This strategy significantly boosted screening hit rates by capturing functional convergence that traditional structure-centric paradigms missed.

Predicting these morphological changes directly from chemical structures remains incredibly difficult because structural descriptors fail to capture downstream biological complexity. To solve this, Xuesong Wang et al. developed Prediction of cellular morphology changes under perturbations with a transcriptome-guided diffusion model, using gene expression data as an intermediary roadmap to accurately simulate how cells change shape under chemical perturbations.

Network-Driven Action and Historical Track Records

If a molecule's functional identity is defined by its systemic interactions, then predicting its behavior requires embedding it within biological networks.

Semantic Networks and Knowledge Graphs

Molecules do not operate in isolation; they function within a web of targets, enzymes, and pathways. Bin Chen et al. demonstrated in Assessing Drug Target Association Using Semantic Linked Data that biological signatures derived from multi-source semantic networks can cluster drugs by their therapeutic indications even when their chemical structures are completely different.

Similarly, Xuan Lin et al. developed KGNN: Knowledge Graph Neural Network for Drug-Drug Interaction Prediction to capture high-order topological relationships that traditional similarity models miss. By analyzing how drugs share metabolic pathways or protein targets within a knowledge graph, the model accounts for the actual biological mechanisms driving drug interactions.

This network context is vital for defining what makes a molecule "drug-like." As Sun Kim argued in BounDr.E: Predicting Drug-likeness via Biomedical Knowledge Alignment and EM-like One-Class Boundary Optimization, models that rely solely on molecular structure ignore the critical biomedical context of how a compound interacts with biological targets, failing to capture its true therapeutic potential.

Bioactivity as a Robust Signal

A molecule's historical performance across previous biological assays can serve as a more powerful descriptor than its physical structure. Huikun Zhang et al. leveraged this insight in Predicting kinase inhibitors using bioactivity matrix derived informer sets, showing that a molecule's functional track record across a diverse set of historical targets provides a far more accurate signal for predicting its activity on a brand-new target than traditional 2D chemical structure similarity. The biological profile inherently integrates the complex, sub-structural electronic features that drive bioactivity, which are often lost in standard molecular fingerprints.

This principle is further validated when predicting adverse events. In Novel deep learning model for more accurate prediction of drug-drug interaction effects, Chihyun Park et al. showed that drugs with distinct chemical structures result in identical interaction effects if they converge on the same biological pathways or target genes. They proved that functional similarity in the gene ontology space is a significantly more robust predictor of adverse drug events than structural similarity.

The Mathematical Formulation of Function

To make functional pathway convergence computationally actionable, researchers calculate similarity using composite metrics that evaluate multi-layered biological data. In Drug voyager: a computational platform for exploring unintended drug action, Min Oh et al. formalized this by calculating functional similarity through a combination of gene overlap, biological process similarity, and established pathway convergence.

By shifting from a single-metric structural comparison to a multi-metric functional analysis, their framework significantly outperformed traditional models in identifying active compounds for specific diseases. This mathematical shift confirms that mapping molecules to their downstream biological effects provides a more robust, predictive, and biologically accurate framework for drug discovery than analyzing molecular geometry alone.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 29 papers
  2. Version 1 · 2026-10-04 · 35 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_structural_functional_divergence_66f705e6,
  title = {structural-functional divergence},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/structural-functional-divergence/rdr_66f705e69b184e4599d288adde87803f},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 2, frozen text):

@misc{lacuna_structural_functional_divergence_66f705e6_v2,
  title = {structural-functional divergence},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/structural-functional-divergence/rdr_66f705e69b184e4599d288adde87803f/v/2},
  note = {Version 2, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake